RxDoctor Payments Data

Theresa le, MD

Family Medicine · Keller, TXNPI 1487098570

Payments from drug & device makers

$1,043in general payments, 2019–2025

Across 46 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$167
  • Pfizer$143
  • E.r. Squibb & Sons, L.L.C.$125
  • GSK$113
  • Novo Nordisk$81
  • Scilex Pharmaceuticals Inc.$66
  • plus $348 from 13 others

What the payments were for

  • Food & beverage$1,043100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,043 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$47,674
Medicare patients
137
Services billed
641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$42,656
JardianceEmpagliflozin16$22,734
EliquisApixaban12$19,352
Breo ElliptaFluticasone/Vilanterol14$5,791
Atorvastatin Calcium222$2,440
Omeprazole94$2,107
Galantamine Hbr13$1,772
Trazodone Hcl92$1,609
Losartan Potassium94$1,087
Montelukast Sodium65$1,080
Alendronate Sodium85$1,033
Levothyroxine Sodium141$1,020
Gabapentin56$965
Albuterol Sulfate HfaAlbuterol Sulfate31$927
Pravastatin Sodium92$840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$81$42,65619 claims
Boehringer IngelheimJardiance$41$22,73416 claims
PfizerEliquis$143$19,35212 claims
GSKBreo Ellipta$113$5,79114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Keller

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →